NCT00263783 - Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

April 30, 2002

Study Completion Date

June 30, 2002

Conditions

Cancer

Interventions

DRUG

MEDI-522

MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuf